NASDAQ:LGND - Ligand Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $223.75
  • Forecasted Upside: 57.66 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$141.92
▲ +1.41 (1.00%)

This chart shows the closing price for LGND by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ligand Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LGND and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LGND

Analyst Price Target is $223.75
▲ +57.66% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Ligand Pharmaceuticals in the last 3 months. The average price target is $223.75, with a high forecast of $310.00 and a low forecast of $180.00. The average price target represents a 57.66% upside from the last price of $141.92.

This chart shows the closing price for LGND for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Ligand Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2021BarclaysBoost Price TargetOverweight$174.00 ➝ $180.00Low
9/14/2021HC WainwrightReiterated RatingBuy$310.00Low
8/31/2021HC WainwrightReiterated RatingBuy$310.00High
7/30/2021Roth CapitalLower Price TargetBuy$200.00 ➝ $190.00High
7/19/2021HC WainwrightReiterated RatingBuy$310.00Medium
5/4/2021BarclaysLower Price TargetOverweight$198.00 ➝ $190.00High
4/14/2021StephensInitiated CoverageOverweightHigh
2/4/2021Craig HallumBoost Price Target$195.00 ➝ $215.00Medium
2/4/2021Roth CapitalBoost Price TargetBuy$195.00 ➝ $200.00Medium
2/4/2021BarclaysBoost Price TargetOverweight$145.00 ➝ $198.00Low
2/4/2021HC WainwrightBoost Price TargetBuy$229.00 ➝ $310.00Low
10/21/2020Craig HallumLower Price TargetBuy$215.00 ➝ $195.00High
10/6/2020BarclaysInitiated CoverageOverweight$156.00Medium
9/29/2020Roth CapitalBoost Price TargetBuy$190.00 ➝ $195.00Low
8/14/2020Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
8/11/2020HC WainwrightReiterated RatingBuy$229.00High
8/4/2020Roth CapitalBoost Price TargetBuy$180.00 ➝ $190.00Medium
8/4/2020BarclaysBoost Price TargetOverweight$134.00 ➝ $145.00Medium
8/3/2020HC WainwrightReiterated RatingBuy$229.00Medium
7/14/2020BenchmarkBoost Price TargetBuy$135.00 ➝ $155.00Low
6/15/2020HC WainwrightReiterated RatingBuy$229.00Low
5/29/2020HC WainwrightReiterated RatingBuy$229.00Low
4/8/2020HC WainwrightLower Price Target$237.00 ➝ $229.00High
4/6/2020HC WainwrightLower Price TargetBuy$237.00 ➝ $229.00Medium
3/24/2020ArgusDowngradeBuy ➝ HoldHigh
3/9/2020GuggenheimInitiated CoverageNeutralHigh
2/28/2020BenchmarkReiterated RatingBuy$135.00High
2/12/2020HC WainwrightReiterated RatingBuy$237.00Low
2/10/2020Roth CapitalLower Price TargetBuy$185.00 ➝ $180.00Medium
2/6/2020BenchmarkInitiated CoverageBuy$135.00Low
1/29/2020Roth CapitalLower Price Target$190.00 ➝ $185.00Low
1/16/2020HC WainwrightReiterated RatingBuy$214.00Medium
1/3/2020HC WainwrightReiterated RatingBuy$214.00Low
9/19/2019BarclaysUpgradeEqual Weight ➝ Overweight$110.00 ➝ $132.00High
8/5/2019BarclaysLower Price TargetEqual Weight$131.00 ➝ $110.00High
6/11/2019BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$131.00High
6/10/2019ArgusSet Price TargetBuy$140.00Medium
5/3/2019HC WainwrightReiterated RatingBuy ➝ Buy$254.00 ➝ $214.00High
3/13/2019HC WainwrightReiterated RatingBuy$254.00Low
3/7/2019Roth CapitalLower Price TargetBuy$195.00 ➝ $180.00Low
3/6/2019HC WainwrightReiterated RatingBuy ➝ Buy$281.00 ➝ $254.00High
2/13/2019ArgusReiterated RatingBuy$200.00 ➝ $150.00Low
11/19/2018HC WainwrightSet Price TargetBuy$281.00High
11/5/2018HC WainwrightReiterated RatingBuy$281.00High
10/29/2018HC WainwrightSet Price TargetBuy$280.00Medium
10/29/2018Roth CapitalUpgradeNeutral ➝ Buy$250.00 ➝ $195.00Medium
10/18/2018HC WainwrightSet Price TargetBuy$280.00Low
10/2/2018HC WainwrightBoost Price TargetBuy ➝ Buy$270.00 ➝ $280.00Medium
9/19/2018HC WainwrightSet Price TargetBuy$257.00 ➝ $270.00Low
9/11/2018ArgusSet Price TargetBuy ➝ Buy$260.00 ➝ $300.00Low
8/17/2018The Goldman Sachs GroupInitiated CoverageNeutral$256.00High
8/8/2018Roth CapitalReiterated RatingBuy ➝ NeutralHigh
8/8/2018StephensReiterated RatingBuy$248.00High
8/7/2018HC WainwrightReiterated RatingBuy$249.00Medium
8/7/2018Craig HallumBoost Price TargetBuy$230.00 ➝ $260.00Medium
7/27/2018HC WainwrightSet Price TargetBuy$249.00High
7/18/2018HC WainwrightSet Price TargetBuy$245.00High
6/28/2018HC WainwrightReiterated RatingBuyHigh
6/27/2018Craig HallumReiterated RatingBuy$230.00High
6/21/2018ArgusInitiated CoverageBuyLow
5/9/2018HC WainwrightReiterated RatingBuy$182.00High
3/7/2018HC WainwrightBoost Price TargetBuy ➝ Buy$170.00 ➝ $182.00Medium
3/7/2018Craig HallumReiterated RatingBuy$190.00 ➝ $200.00Medium
2/26/2018Roth CapitalBoost Price TargetBuy$158.00 ➝ $171.00Low
2/22/2018Craig HallumBoost Price TargetBuy$170.00 ➝ $190.00Medium
2/2/2018HC WainwrightReiterated RatingBuy$170.00Low
1/24/2018HC WainwrightBoost Price TargetBuy ➝ Buy$159.00 ➝ $170.00Low
1/18/2018HC WainwrightReiterated RatingBuy$169.00Low
1/12/2018HC WainwrightSet Price TargetBuy$169.00Low
1/3/2018HC WainwrightSet Price TargetBuy ➝ Buy$169.00High
12/27/2017HC WainwrightSet Price TargetBuy ➝ Buy$163.00 ➝ $169.00Medium
11/28/2017HC WainwrightSet Price TargetBuy$163.00Low
11/22/2017HC WainwrightReiterated RatingBuy$159.00N/A
11/20/2017Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell$105.00N/A
11/15/2017Craig HallumReiterated RatingBuy$160.00 ➝ $170.00N/A
11/15/2017HC WainwrightSet Price TargetBuy$159.00N/A
11/13/2017Roth CapitalSet Price TargetBuy$158.00N/A
11/6/2017HC WainwrightReiterated RatingBuy$157.00N/A
10/24/2017HC WainwrightSet Price TargetBuy$157.00N/A
10/18/2017HC WainwrightSet Price TargetBuy$157.00N/A
10/11/2017Roth CapitalReiterated RatingBuy$135.00 ➝ $158.00N/A
10/5/2017HC WainwrightReiterated RatingBuy$157.00N/A
9/5/2017HC WainwrightReiterated RatingBuy ➝ Buy$150.00Medium
8/9/2017StephensReiterated RatingOverweight$125.00 ➝ $137.00Low
8/8/2017Deutsche Bank AktiengesellschaftBoost Price TargetHold$103.00 ➝ $104.00High
8/8/2017Roth CapitalBoost Price TargetBuy$120.00 ➝ $135.00High
7/17/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$100.00 ➝ $103.00Low
5/22/2017Roth CapitalSet Price TargetBuy$120.00Low
2/27/2017Roth CapitalInitiated CoverageBuy$118.00N/A
11/21/2016Roth CapitalSet Price TargetBuy$154.00N/A
10/28/2016Roth CapitalSet Price TargetBuy$154.00N/A
10/5/2016Craig HallumBoost Price Target$150.00 ➝ $160.00N/A
10/5/2016HC WainwrightReiterated RatingBuy$146.00 ➝ $160.00N/A
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 ➝ $125.00N/A
9/28/2016Roth CapitalReiterated RatingBuy$151.00 ➝ $150.00N/A
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 5 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 5 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Ligand Pharmaceuticals logo
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $141.92
Low: $140.14
High: $141.92

50 Day Range

MA: $123.09
Low: $102.33
High: $144.73

52 Week Range

Now: $141.92
Low: $78.26
High: $219.75

Volume

1,217 shs

Average Volume

330,932 shs

Market Capitalization

$2.37 billion

P/E Ratio

51.23

Dividend Yield

N/A

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Ligand Pharmaceuticals?

The following equities research analysts have issued research reports on Ligand Pharmaceuticals in the last year: Barclays PLC, Craig Hallum, HC Wainwright, Roth Capital, Stephens, and Zacks Investment Research.
View the latest analyst ratings for LGND.

What is the current price target for Ligand Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Ligand Pharmaceuticals in the last year. Their average twelve-month price target is $223.75, suggesting a possible upside of 59.2%. HC Wainwright has the highest price target set, predicting LGND will reach $310.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $180.00 for Ligand Pharmaceuticals in the next year.
View the latest price targets for LGND.

What is the current consensus analyst rating for Ligand Pharmaceuticals?

Ligand Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LGND will outperform the market and that investors should add to their positions of Ligand Pharmaceuticals.
View the latest ratings for LGND.

What other companies compete with Ligand Pharmaceuticals?

How do I contact Ligand Pharmaceuticals' investor relations team?

Ligand Pharmaceuticals' physical mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 550-7500 and its investor relations email address is [email protected] The official website for Ligand Pharmaceuticals is www.ligand.com.